Hook & thesis
Centene has staged an impressive recovery from last summer's low, and the move into the mid-$60s looks sustainable rather than a short-lived bounce. The stock sits near its 52-week high ($66.55 on 06/09/2026) after a string of positive policy and operational developments that collectively improve revenue visibility for 2027 and beyond.
The trade here is a disciplined swing long: buy near current levels, keep a conservative stop below $60, and aim for a reasonable upside to $75 over the next 45 trading days. The combination of attractive valuation metrics, sizable free cash flow and a CMS Medicare capitation boost argues the rally has fundamentals behind it — not just momentum chasing.
What Centene does and why the market should care
Centene Corporation is a large managed-healthcare company that operates across Medicaid, Medicare Advantage, commercial plans and a suite of ancillary services including pharmacy, dental and behavioral health. The company's Medicaid footprint — state-sponsored plans and expansions — remains the largest revenue driver, with Medicare Advantage now an increasingly important margin contributor.
Investors pay attention because Centene sits at the intersection of healthcare policy and cyclical enrollment flows. Small changes in CMS reimbursement, risk-adjustment rules or membership counts can swing margins materially. That said, Centene's scale provides negotiating leverage with states and pharmacy counterparts, and that scale is showing up in cash generation.
Key numbers supporting the thesis
- Current price: $65.54; 52-week high/lows: $66.55 / $25.08.
- Market capitalization: roughly $32.33B.
- Valuation: price-to-sales ~ 0.16, EV-to-sales ~ 0.13, EV/EBITDA ~ 9.22.
- Cash generation: reported free cash flow of $7.112B — large relative to enterprise value (EV ~ $26.48B).
- Balance sheet: debt-to-equity ~ 0.76, current ratio ~ 2.37, and reported cash ~ $1.2B.
- Profitability signals: GAAP EPS is negative (reported EPS - $13.05), and trailing ROE/ROA are negative; but company guidance has signaled a path back to positive adjusted EPS.
Interpretation
Those valuation multiples are low for a company of Centene's scale. Price-to-sales of 0.16 is inexpensive — the market is assigning a modest multiple to Centene's revenue base. At the same time, free cash flow of $7.1B is substantial versus an EV of roughly $26.5B, indicating the business is generating material cash that can be deployed for debt reduction, buybacks, or reinvestment.
Catalysts to drive the trade
- CMS Medicare payment clarity - On 04/07/2026 CMS announced a 2.48% increase in 2027 Medicare Advantage capitation rates (and ~4.98% when accounting for risk trends). That materially improves revenue visibility for Medicare products and reduces the uncertainty premium applied to Centene.
- Policy stability and risk-adjustment retention - CMS retaining the 2024 risk adjustment model helps earnings predictability, which is positive for insurers that rely on Medicare Advantage margins.
- Improving market sentiment - Centene was among the top large-cap gainers in late April/early May, reflecting investor willingness to re-rate the stock on better-than-expected quarterly execution and guidance.
- Longer-term addressable growth areas - Expansion in healthcare transportation and other services markets supports ancillary revenue opportunities over the coming years.
Trade plan (actionable)
| Position | Entry | Stop-loss | Target | Horizon |
|---|---|---|---|---|
| Long | $65.54 | $59.50 | $75.00 | Mid term (45 trading days) |
Rationale: the entry uses the intraday traded price near the breakout region; the stop at $59.50 protects capital below the 10-day/21-day moving average region and allows for normal pullback volatility. The target at $75 is a practical upside of ~14% from the entry and gives room for multiple expansion as the market digests CMS tailwinds and cash-flow conversion continues.
Position sizing & risk framing
This is a medium risk trade. Centene can swing dramatically on membership or CMS news, so size the position to a level where a stop-out (loss to $59.50) is acceptable relative to your portfolio risk tolerance. The reward-to-risk here is about 1.6x (approx +14% potential vs -9% downside to the stop).
Technical and market context
Momentum indicators show the stock is heated but not exhausted: the 10- and 20-day averages are climbing ($63.22 and $60.88 respectively), RSI sits near 68 (approaching overbought), and MACD shows a small negative histogram even as the MACD line remains elevated. Average daily volume over recent periods (~5.5M) implies sufficient liquidity for a swing-sized position, while short interest and short volume spikes suggest periods of tactical squeezes are possible.
Risks and counterarguments
- Membership decline in Medicaid - Centene previously reported Medicaid membership dropping to 12.52M from 13.00M, which reduces premium revenue and can compress near-term margins. A renewed trend of enrollment declines would undermine the thesis.
- Profitability headwinds - GAAP EPS remains negative (-$13.05), and key profitability metrics such as ROE are negative. If margins don't recover or if health benefits ratio stays elevated (reported at ~94.3 in a past quarter), improved top-line visibility won't translate to EPS gains.
- Regulatory uncertainty - CMS guidance can move markets quickly. A future CMS adjustment that reduces capitation growth or tighter risk model changes would hurt the stock.
- Operational risks - Integration issues, pharmacy price shocks, or an adverse claims cycle could erode cash flow despite the current strong free cash flow reading.
- Technical pullback risk - With RSI high and price close to a 52-week high, short-term pullbacks are likely. The stop is designed to protect against such retracements, but whipsaw remains a realistic outcome.
Counterargument: Critics will point to the negative GAAP earnings and past membership declines as proof the rally is primarily sentiment-driven. That is fair — if Centene cannot return to consistent adjusted earnings growth and shrink its health benefits ratio, the valuation multiple could compress again. However, the company's large free cash flow and the Medicare capitation uplift materially reduce the odds that upside is purely speculative. If management converts a portion of that cash flow into balance sheet repair and shareholder-friendly actions, the re-rating is credible.
What would change my mind
I would exit the thesis and reassess if any of the following occurs: a) a fresh and sustained decline in Medicaid enrollment beyond the company’s recent guidance window; b) a negative CMS decision that reduces expected Medicare Advantage revenue growth materially; c) a quarter where the health benefits ratio either fails to improve or spikes further and adjusted EPS guidance is lowered; or d) cash flow generation weakens meaningfully. Conversely, sustained positive membership trends, continued FCF conversion and incremental clarity on Medicare rate trajectory would reinforce the bullish case and could justify tightening the stop or adding to the position.
Conclusion
Centene's comeback is backed by credible fundamentals: policy tailwinds in Medicare, attractive valuation metrics (low P/S and EV/S), and substantial free cash flow. The stock is not without risk — membership trends, profitability and regulatory shifts matter — but the risk/reward at current levels supports a tactical swing long. The trade outlined is disciplined: enter near $65.54, stop at $59.50, target $75 over a mid-term 45 trading day window. Manage position size, respect the stop, and let evolving membership and CMS developments inform any adjustments.
Key points
- Centene trades near $65.54 with a market cap ~ $32.33B and EV ~ $26.48B.
- Valuation is inexpensive: price-to-sales ~ 0.16 and EV/EBITDA ~ 9.22; free cash flow of ~$7.1B supports the multiple.
- Catalysts: CMS Medicare capitation increase, policy clarity, and improving market sentiment.
- Primary risks: Medicaid membership decline, negative GAAP earnings, regulatory changes and operational/claims volatility.
- Trade: Long at $65.54, stop $59.50, target $75.00, mid term (45 trading days).